KEYNOTE-062 Highlights Role of Pembrolizumab in Gastric/GEJ Cancer Subtypes
David H. Ilson, MD, PhD, discusses the current role of pembrolizumab in patients with gastric cancer or gastroesophageal junction adenocarcinoma based on the results from the KEYNOTE-062 trial.
Expert Shares Main Takeaway From Phase III TAGS Trial in Patients With Gastric/GEJ Cancer
David H. Ilson, MD, PhD, discusses the main takeaway from the data for phase III TAGS trial reported at the 2019 Gastrointestinal Cancers Symposium.